GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.

A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.

The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.

The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.